A randomised, double-blind, placebo-controlled, two-way crossover study, to evaluate the effect of a single oral dose of BNC210 on CCK-4 induced panic-like symptoms in healthy young male subjects.

Trial Profile

A randomised, double-blind, placebo-controlled, two-way crossover study, to evaluate the effect of a single oral dose of BNC210 on CCK-4 induced panic-like symptoms in healthy young male subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2011

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders; Panic symptoms
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Nov 2011 Results were reported at the 41st Annual Meeting of the Society for Neuroscience, according to a Bionomics media release.
    • 30 Mar 2011 Primary endpoint 'Symptom-rate' has been met.
    • 30 Mar 2011 Positive preliminary results have been reported in a Bionomics media release; the company anticipates that data from this trial will be presented at a major scientific conference later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top